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20-Hydroxyvitamin D3, a Product of Vitamin D3
Hydroxylation by Cytochrome P450scc, Stimulates
Keratinocyte Differentiation
Blazej Zbytek1, Zorica Janjetovic1, Robert C. Tuckey2, Michal A. Zmijewski1, Trevor W. Sweatman3,
Emily Jones1, Minh N. Nguyen2 and Andrzej T. Slominski1
It has been shown that mammalian cytochrome P450scc can metabolize vitamin D3 to 20-hydroxyvitamin D3
(20(OH)D3) and 20,22(OH)2D3. To define the biological significance of this pathway, we tested the effects of
20(OH)D3 on the differentiation program of keratinocytes and on the expression of enzymes engaged in
vitamin D3 metabolism. Immortalized HaCaT and adult human epidermal keratinocytes were used as a model
and the effects of 20(OH)D3 were compared with those of 25(OH)D3 and 1,25(OH)2D3. 20(OH)D3 inhibited
proliferation and caused G2/M arrest. 20(OH)D3 stimulated involucrin and inhibited cytokeratin 14 expression.
The potency of 20(OH)D3 was comparable to that of 1,25(OH)2D3. 20(OH)D3 decreased the expression of
cytochrome P450 enzyme (CYP)27A1 and CYP27B1, however, having only slight effect on CYP24. The effect of
20(OH)D3 was dependent on the vitamin D receptor (VDR). As shown by electrophoretic mobility shift assay,
20(OH)D3 stimulated the binding of nuclear proteins to the VDRE. Transfection of cells with VDR-specific siRNA
decreased 20(OH)D3-stimulated transcriptional activity of the VDRE promoter and the expression of involucrin
and CYP24 mRNA. Therefore, the above studies identify 20(OH)D3 as a biologically active secosteroid that
induces keratinocyte differentiation. These data imply that the previously unreported pathway of vitamin D3
metabolism by P450scc may have wider biological implications depending, for example, on the extent of adrenal
gland or cutaneous metabolism.
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INTRODUCTION
Recent studies have revealed that mammalian cytochrome
P450scc (cytochrome P450 enzyme (CYP)11A1), in addition
to its role in the conversion of cholesterol to pregnenolone for
steroid synthesis, can also metabolize vitamins D2 and D3, as
well as their provitamin precursors ergosterol and
7-dehydrocholesterol (Guryev et al., 2003; Slominski et al.,
2004, 2005a, b, 2006). P450scc converts vitamin D3 to
20-hydroxyvitamin D3 (20(OH)D3) and di- and tri-hydroxy-
vitamin D3 in a sequential and stereospecific manner, with
the initial formation of 20(OH)D3 (Slominski et al., 2005b).
20(OH)D3 is the major product of the reaction, indicating
that it can be released from the active site of the enzyme, with
only a minor portion remaining (or rebinding) for further
hydroxylation. It is also the only product of vitamin D3
hydroxylation detected in incubations of isolated adrenal
mitochondria. Thus, in organs expressing high levels of
P450scc, such as adrenal cortex, corpus luteum, follicles, and
placenta, production of 20(OH)D3 could possibly have
systemic effects, whereas in organs expressing low levels of
P450scc, such as skin (Slominski et al., 2004), it could serve
local para-, auto-, or intracrine roles.
In humans, vitamin D3 is derived predominantly from its
precursor 7-dehydrocholesterol, which is localized to the
plasma membrane of basal epidermal keratinocytes (Holick,
2003b). The UVB component (290–320 nm) of solar radiation
induces 7-dehydrocholesterol photolysis to previtamin D3,
which then undergoes internal rearrangement to form vitamin
D3 at normal skin temperature (Holick et al., 1980; Holick,
2003b). After entering the circulation, vitamin D3 can be
hydroxylated in the liver to 25-hydroxyvitamin D3
(25(OH)D3) by mitochondrial CYP27A1 (Holick, 2003b;
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Feldman et al., 2005). Several microsomal cytochromes P450
(CYP2R1, CYPC11, CYP3A4, CYP2D25, and CYP2J3) also
exhibit 25-hydroxylase activity on vitamin D3 (Ohyama and
Yamasaki, 2004; Prosser and Jones, 2004). 25(OH)D3 is then
hydroxylated in the kidney to the active form, 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3), by mitochondrial
CYP27B1 (Feldman et al., 2005). At the cellular level,
1,25(OH)2D3 binds to specific vitamin D receptors (VDRs)
that heterodimerize with the retinoid X receptors. Receptor–
vitamin complexes affect expression of genes that have
vitamin D response elements (VDREs) in their promoter
(Christakos et al., 2003). 1,25(OH)2D3 is also synthesized
locally by epidermal keratinocytes, which contain both
CYP27A1 and CYP27B1 (Bikle et al., 1986; Lehmann,
2005; Bikle, 2006; Holick, 2006). The 1a-hydroxylase
activity required to convert 25(OH)D3 to 1,25(OH)2D3 has
also been detected in many other peripheral tissues (Bikle
et al., 1986; Lehmann, 2005). CYP24 hydroxylates
1,25(OH)2D3 as well as 25(OH)D3 to yield metabolically
inactive products in the kidney or in a plethora of peripheral
tissues (Ohyama and Yamasaki, 2004; Ebert et al., 2006).
1,25(OH)2D3 stimulates CYP24 gene expression and inhibits
the expression of both CYP27B1 and CYP27A1 genes
(reviewed by Feldman et al., 2005; Bikle, 2006; Ebert et al.,
2006; Holick, 2006).
Although the biological role of 20(OH)D3 is unknown, it is
well documented that 1,25(OH)2D3 and its derivatives have
immune and neuroendocrine activities, and tumorostatic and
anticarcinogenic properties, affecting proliferation, differen-
tiation, and apoptosis in cells of different lineages, and
protecting DNA against oxidative damage (Wiseman, 1993;
Holick, 2003a, b; Bikle, 2004). 1,25(OH)2D3 and its deriva-
tives also have significant local actions on the formation and
functional differentiation of adnexal structures and the
epidermis, modulation of skin immune system, and protection
against UVB-induced DNA damage (Holick, 2000, 2003a, b;
Bikle et al., 2001; Bikle, 2004). For example, 1,25(OH)2D3 is
recognized as an inhibitor of keratinocyte proliferation and as
a stimulator of keratinocyte differentiation (Bikle, 2004; Bikle
et al., 2004). It is known to induce both G1/0 and G2/M arrest
in keratinocytes (Kobayashi et al., 1994; Dai et al., 2004).
Keratinocyte differentiation is characterized by step-by-step
morphological changes, which are accompanied by gradual
changes in the expression of genes coding for constituents of
the keratinocyte cytoskeleton and accessory envelope cross-
linkage-related proteins (Bikle, 2004; Eckert et al., 2004).
Early keratinocyte differentiation involves a decrease in the
expression of cytokeratins 5 and 14, and increased expression
of cytokeratins 1 and 10, and involucrin.
Thus, the information listed above has mandated testing
for the phenotypic activity of 20(OH)D3 in comparison to the
well-defined biological effects of 1,25(OH)2D3. As a model,
we used immortalized human HaCaT keratinocytes and
primary cell lines of adult human epidermal keratinocytes.
Effects of 1,25(OH)2D3 on both the expression of genes
involved in its metabolism and, as mentioned above, in the
differentiation program, have previously been studied in
these cells (Bikle, 2004; Bar et al., 2007). We also compared
the effects of 20(OH)D3 with those of 25(OH)D3 to establish
the role of the hydroxy group at C20, as opposed to C25, on
biological activity.
RESULTS AND DISCUSSION
20(OH)D3 was obtained by enzymatic hydroxylation of
vitamin D3 by bovine cytochrome P450scc, as described
previously (Slominski et al., 2005b). The product identity and
purity was confirmed by reversed-high-performance liquid
chromatography (HPLC), UV spectrometry, and mass spectro-
scopic analyses (Figure 1). Specifically, 20(OH)D3 was
eluted as a single peak with retention time of 37minutes
and UV spectrum with maximum at the 260–270nm region
characteristic for vitamin D3 derivatives. The predicted
molecular mass of 20(OH)D3 (400Da) corresponded to
detected ions at m/z 383 ([MþH]þH2O) and m/z 365
([Mþ1]þ2H2O).
20(OH)D3 inhibits proliferation of epidermal keratinocytes
HaCaT keratinocytes were incubated for 48 hours in DMEM
medium. DNA synthesis was then measured with a [3H]thy-
midine assay. As shown in Figure 2a, 20(OH)D3 inhibited
DNA synthesis at the concentrations of 108 and 107 M. To
further define the antiproliferative effect of the ligands,
HaCaT keratinocytes were incubated for 10 days in DMEM
in the presence or absence of vitamin D3 hydroxy derivatives
and colony-forming potential was measured. As shown in
Figure 2b and c, 20(OH)D3 inhibited colony formation by
HaCaT cells. 20(OH)D3 at 108 M inhibited colony formation
by 36% and at 107 M by 58%. 1,25(OH)2D3 at 108 M
inhibited colony formation by 64%, whereas 25(OH)D3 had
no significant effect (Figure 2d). Thus, 20(OH)D3 shows
antiproliferative potency comparable to but lower than
1,25(OH)2D3.
Next, we tested the effect of 20(OH)D3 on normal
epidermal keratinocytes using the technique of flow cyto-
metry. The cells were seeded into Petri dishes and, after
48 hours of treatment with 20(OH)D3 or vehicle, were
collected, fixed, stained with propidium iodide, and sub-
mitted for flow-cytometric analysis. Control cells were
distributed as follows: 37±10% in G1/0, 38±14% in S,
and 25±6% in the G2/M phase of the cell cycle (n¼ 3).
Treatment of cells for 24 hours with 10 nM 1,25(OH)2D3
resulted in significant G1/0 (52±2%, Po0.05) and G2/M
(35±5%, Po0.05) arrests (S phase: 13±7%, Po0.05).
Similarly, treatment of cells for 48 hours with 10 nM
20(OH)D3 resulted in G1/0 (52±5%) and G2/M (35±8%,
Po0.05) arrests (S phase: 13±12%, Po0.05).
20(OH)D3 affects the expression of genes involved in
keratinocyte differentiation
Since 1,25(OH)2D3 is a recognized stimulant of keratinocyte
differentiation and its effects on the expression of proteins
engaged in the formation of mature keratinocyte phenotype
have been studied widely (Bikle, 2004), we compared
the action of 20(OH)D3 with that of 1,25(OH)2D3 on the
expression of involucrin and cytokeratin 14 genes in normal
epidermal keratinocytes. 20(OH)D3 inhibited the expression
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of cytokeratin 14 and stimulated the expression of involucrin
in a dose- and time-dependent manner. 20(OH)D3 at 1010 M
inhibited the expression of cytokeratin 14 mRNA. The effect
was maximal 1 hour after treatment (for example, decreased
to 45% of the control value) and started to fade at 6 hours,
reaching 62% of the control. The inhibitory effect was
significant at both 1010 and 108 M concentrations. Of note,
20(OH)D3 showed significantly higher inhibitory effect on
cytokeratin 14 mRNA expression than the 1,25(OH)2D3. As
shown in Figure 3, 20(OH)D3 (at 108M but not at 1010 M)
stimulated the expression of involucrin mRNA. The effect was
maximal at 6 hours when 4.7-fold stimulation was observed,
and started to fade by 24 hours when stimulation was only
1.8-fold (Figure 3a). Again, 20(OH)D3 has higher potency in
inhibiting involucrin mRNA expression in comparison with
1,25(OH)2D3 (B4.7- versusB3.1-fold stimulation, Po0.05)
(Figure 3c). 25(OH)D3 increased the expression of involucrin
B2.1-fold; however, the effect was statistically insignificant
(Figure 3c).
20(OH)D3 stimulates involucrin production and increases
keratinocyte size and granularity
Having established that 20(OH)D3 acts at the transcriptional
level, we examined whether the changes in the gene
expression were reflected in the keratinocyte differentiated
phenotype. We thus measured the expression of involucrin
using both flow cytometry and fluorescence microscopy. As
shown in Figure 4, treatment of HaCaT keratinocytes with
20(OH)D3 at 108 M for 24 hours resulted in an B3.7-fold
increase in the expression of involucrin (control differential
mean fluorescence intensity 19±9; treatment differential
mean fluorescence intensity 71±8, n¼ 4, Po0.05).
Interestingly, the effects of 1,25(OH)2D3 and 25(OH)D3
were negligible in this experiment. Moreover, we measured
the effects of 20(OH)D3 on forward and side scatter of cells,
parameters that reflect cell size and granularity, respectively.
Both parameters are known to increase during keratinocyte
differentiation. Mean signal intensity (MSI) of forward scatter
in control cells was 235±7 and of side scatter was 175±7
(n¼3). 20(OH)D3 at 0.1 nM significantly increased both
forward (MSI: 251±2, Po0.05) and side scatter of HaCaT
keratinocytes (MSI: 210±6, Po0.05). 1,25(OH)2D3 acted
similarly but only the effect on side scatter was statistically
significant (MSI: 219±4, Po0.05). 25(OH)D3 also increased
both parameters, although only the effect on forward scatter
was statistically significant (MSI: 254±0.06, Po0.05).
Most of the actions of 1,25(OH)2D3 on keratinocyte
differentiation we report here have been documented
previously (Bikle, 2004). As far as the actions of 25(OH)D3
are concerned, we show that this compound generally acts
similarly to 1,25(OH)2D3, albeit at lower potency. This
agrees with previous studies, which show that 25(OH)D3
inhibits keratinocyte proliferation and stimulates keratinocyte
differentiation (Itin et al., 1994; Pillai et al., 1996). This study
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Figure 1. Identity and purity of 20(OH)D3 used for biological testing. The final reversed-phase-HPLC product with a retention time of B37minutes (thick
arrow) had UV (top inset) and mass spectra (lower inset) characteristic of 20(OH)D3. The structure of this compound was previously defined by nuclear magnetic
resonance analysis as 20(OH)D3 (5Z, 7E-9,10-seco-5,7,10(19)-cholestatriene-3,20S-diol) (see inset) (Slominski et al., 2005b).
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shows for the first time that 20(OH)D3 has similar effects on
programmed keratinocyte differentiation to 1,25(OH)2D3
and also has comparable potency.
20(OH)D3 inhibits the expression of CYP27B1 and CYP27A1
genes
Since expression of CYP27B1 and CYP27A1 genes is
inhibited by 1,25(OH)2D3 in the kidney and liver, respec-
tively (Feldman et al., 2005; Holick, 2006), we compared the
action of 20(OH)D3 with that of 1,25(OH)2D3 on the
expression of these genes in normal epidermal keratinocytes.
20(OH)D3 inhibited the expression of CYP27B1 and
CYP27A1 in a dose- and time-dependent manner (Figure 5).
As shown in Figure 5, 20(OH)D3 at 108 M inhibited the
expression of CYP27B1 B4-fold. The effect was detected at
1 hour after treatment, maintained thereafter, and faded at
48 hours when inhibition decreased to B2-fold (Figure 5a).
Interestingly, 20(OH)D3 showed slightly higher potency
than 1,25(OH)2D3 on CYP27B1 expression (for example,
1,25(OH)2D3 at 108 M inhibited gene expression by B1.5-
fold) (Figure 5c). In contrast, 25(OH)D3 increased the
expression of CYP27B1 by B1.3-fold.
20(OH)D3 at 108 M inhibited the expression of CYP27A1
gradually. The effect was observable at 1 hour after treatment,
with maximum inhibition ofB3.5-fold occurring at 24 hours.
The effect started to fade at 48 hours when inhibition
decreased to B2.6-fold. Similar to the effect on CYP27B1,
the effect of 20(OH)D3 on CYP27A1 expression was also
higher than that of 1,25(OH)2D3 (B2.9-fold at 24 hours with
108 M 1,25(OH)2D3). 25(OH)D3 also decreased the
expression of CYP27A1 by B1.9-fold.
Our results confirm the general actions reported for
1,25(OH)2D3 and 25(OH)D3 on CYP27B1 and CYP27A1
(Feldman et al., 2005; Bikle, 2006; Holick, 2006) using adult
human epidermal keratinocytes. However, other researchers
have reported that 1,25(OH)2D3 does not affect the
expression of CYP27B1 and CYP27A1 in keratinocytes
(Bar et al., 2007). This discrepancy might be explained by
the fact that we studied adult keratinocytes as opposed to the
neonatal keratinocytes used by Bar et al. Adult keratinocytes
may have a fully developed apparatus for 1,25(OH)2D3
synthesis, metabolism, and regulation, and thus provide a
better model for these studies than neonatal keratinocytes.
Nevertheless, the major result of our studies is the demon-
stration for the first time that 20(OH)D3 can act as a potent
inhibitor of both genes involved in 1,25(OH)2D3 synthesis.
20(OH)D3 has significantly lower potency on CYP24
transcription than 25(OH)D3 or 1,25(OH)2D3
Since CYP24 is an important physiological target of
1,25(OH)2D3 in the kidney and peripheral tissues, including
skin (Holick, 2003b, 2006; Feldman et al., 2005; Lehmann,
2005; Bikle, 2006), we compared the action of 20(OH)D3
with those of 1,25(OH)2D3 and 25(OH)D3 on the transcrip-
tional activity of the CYP24 promoter in normal epidermal
keratinocytes. Normal epidermal keratinocytes were trans-
fected with either a luciferase reporter construct driven by
CYP24 promoter or a promoterless luciferase construct.
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Figure 2. 20(OH)D3 inhibits keratinocyte proliferation. HaCaT keratinocytes were treated for 48 hours in DMEM containing 5% charcoal-treated FBS.
[3H]Thymidine was added for last 12 hours of incubation and then DNA synthesis was assessed (a). HaCaT keratinocytes were cultured for 10 days in DMEM
containing 5% charcoal-treated FBS. Then colonies were fixed, stained with crystal violet, and counted. Representative pictures of HaCaT treated with
20(OH)D3 at 108 M or controls are shown (b). Graphs showing the dose-dependent effect (c) and comparison with the effects of other secosteroids at 108 M (d)
are presented. Data are presented as mean±SEM ([3H]thymidine assay, n¼36; colony-forming assay, n¼4); *Po0.05, **Po0.005, and ***Po0.0005.
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Transcriptional activity of the CYP24 promoter was stimu-
lated B21-fold, B12-fold, and only B2.5-fold by
1,25(OH)2D3, 25(OH)D3, and 20(OH)D3, respectively.
None of these substrates affected the activity of the
promoterless (pLuc) construct. Moreover, we tested the effect
of 20(OH)D3 on the expression of CYP24 mRNA. As shown
in Figure 6, 10 nM 20(OH)D3 at 24 hours increased CYP24
mRNA levels only 1.3-fold but at 106 M, B247-fold
stimulation was observed. The effect on CYP24 was thus
significantly weaker, since it required a much higher
concentration of 20(OH)D3. The active form of vitamin D3
(1,25(OH)2D3) stimulates the expression of CYP24 in the
kidney (Feldman et al., 2005), in cultured human neonatal
keratinocytes (Bar et al., 2007), and in other skin and non-
skin cells (Holick, 2003a; Lehmann, 2005; Bikle, 2006; Ebert
et al., 2006). Our study confirms these findings and shows for
the first time that 20(OH)D3 affects CYP24 transcriptional
activity to a significantly lower degree in adult epidermal
keratinocytes as compared with the potency of 1,25(OH)2D3
and 25(OH)D3. In regards to the effect at 10 nM, a slight
discrepancy between the results obtained with the reporter
assay and real-time PCR can be explained by a higher
sensitivity of the promoter-driven construct in our system. In
separate experiments using HaCaT keratinocytes, 20(OH)D3
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Figure 3. 20(OH)D3 stimulates the expression of involucrin mRNA in normal human epidermal keratinocytes. Keratinocytes were incubated in EpiLife
medium containing EpiLife defined growth supplement with either 20(OH)D3, 25(OH)D3, or 1,25(OH)2D3, then lysed, and total RNA was extracted and
reverse transcribed. Involucrin mRNA levels were measured with reagent Hs00846307_s1 according to the manufacturer’s protocol (Applied Biosystems)
and normalized to 18SrRNA content. Data are presented as mean±SEM (n¼ 3). *Po0.05 versus control; **Po0.005 versus control; ***Po0.0005 versus
control; and #Po0.05 versus 1,25(OH)2D3. (a) Time response (at 108 M). (b) Dose response (at 6 hours). (c) Comparison of vitamin D3 hydroxy derivatives
(at 108 M and 6 hours).
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Figure 4. 20(OH)D3 stimulates the expression of involucrin in
keratinocytes. HaCaT keratinocytes were incubated for 48 hours in DMEM
medium containing 5% FBS with 20(OH)D3 or vehicle and then fixed and
stained with involucrin antibody followed by secondary antibody linked to
FITC. Cells were then read with a flow cytometer as described previously.
Data are presented as mean±SEM (n¼4). Inset: Normal epidermal
keratinocytes were treated with 20(OH)D3 or vehicle and then stained with
anti-involucrin antibody followed by secondary antibody linked to FITC. Cells
were photographed as described under Materials and Methods. Original
magnification  20.
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failed to stimulate the CYP24 promoter activity, which
indicates that the stimulatory effect depends on the type of
cells used for the experiment. The above finding suggests that
this previously unidentified compound (20(OH)D3) may play
a minor role in regulating the inactivation of the active forms
of vitamin D3, which is in opposition to its inhibitory actions
on expression of CYP27A1 and CYP27B1 genes (see above).
The discrepancy between the typical set of responses to
1,25(OH)2D3 and to 20(OH)D3 can be explained by
different conformations of ligand–receptor complex eliciting
different cellular responses. This biological mechanism has
been documented in case of the peroxisome proliferator-
activated receptor-g and its different ligands (Guo et al.,
2006). Furthermore, 20(OH)D3 can be metabolized to
different compounds, including di- and tri-hydroxyvitamin
D3 that potentially may interact with the receptor (Slominski
et al., 2005b).
20(OH)D3 stimulates the VDRE and involucrin and CYP24
mRNAs through the VDR in HaCaT keratinocytes
HaCaT keratinocytes were stimulated for 24 hours with 10 nM
20(OH)D3, and then nuclear extracts were prepared and
incubated with labeled VDRE probe. As shown in Figure 7a,
20(OH)D3 stimulated the binding activity of protein com-
plexes to the VDRE probe. The binding was specific since
excess unlabeled VDRE caused complete disappearance of
the signal. Moreover, addition of retinoid X receptor antibody
resulted in a significant decrease in the signal, which
provides evidence that the retinoid X receptor protein is part
of a 20(OH)D3-stimulated protein complex that binds to the
VDRE. As shown in the inset in Figure 7a, the positive
control, 1,25(OH)2D3, stimulated binding of protein
complexes to the VDRE.
Cells were transfected with VDRE-Luc and with scrambled
or VDR small interfering RNA (siRNA). As shown in the
inset of Figure 7b, VDR siRNA caused almost complete
disappearance of VDR expression at the protein level
24 hours after transfection. Keratinocytes were then incu-
bated with 10 nM 20(OH)D3 or the vehicle control for
24 hours. As shown in Figure 7b, transfection of HaCaT
keratinocytes with VDR siRNA had no effect on basal VDRE-
driven transcriptional activity (cells transfected with
scrambled siRNA). Treatment of cells transfected with
scrambled siRNA with 10 nM 20(OH)D3 resulted in B3-fold
increase in VDRE-driven luciferase activity (Po0.005, versus
control). On the other hand, transfection of keratinocytes
with VDR siRNA decreased the 20(OH)D3-stimulated VDRE
activity (Po0.00005). Of note, there was no statistical
significance in transcriptional activity between cells trans-
fected with scrambled siRNA and treated with the vehicle
and cells transfected with VDR siRNA and treated with
20(OH)D3. Furthermore, we have transfected HaCaT
keratinocytes with scrambled or VDR siRNA and then directly
measured the mRNA levels of involucrin and CYP 24.
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Figure 5. 20(OH)D3 inhibits the expression of CYP27B1 mRNA. Normal epidermal keratinocytes were incubated in EpiLife medium containing EpiLife defined
growth supplement with either 20(OH)D3, 25(OH)D3, or 1,25(OH)2D3, then lysed, and total RNA was extracted and reverse transcribed. CYP27B1 mRNA
levels were measured with reagent Hs00168017_m1 according to manufacturer’s protocol (Applied Biosystems) and normalized to 18SrRNA content as
described. Data are presented as mean±SEM (n¼ 3). *Po0.05 versus control; **Po0.005 versus control; and ***Po0.0005 versus control. (a) Time response
(at 108 M). (b) Dose response (at 1 hour). (c) Comparison of relative potencies (at 108 M and 1 hour).
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Control experiments confirmed that VDR gene silencing
attenuates 1,25(OH)2D3-mediated stimulation of involucrin
and CYP24 gene expression (not shown), which is in
agreement with the literature (Bikle et al., 2002; Bikle,
2006). As shown in Figure 8, transfection of HaCaT
keratinocytes with VDR siRNA had no effect on basal mRNA
levels. Treatment of cells transfected with scrambled siRNA
with 10 nM 20(OH)D3 for 24 hours resulted in B3.5-fold
increase in involucrin mRNA (Po0.0005, versus control).
Treatment of cells transfected with scrambled siRNA with
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1 mM 20(OH)D3 for 24 hours resulted in B14-fold increase
in CYP24 mRNA (Po0.0005, versus control). Transfection
of keratinocytes with VDR siRNA decreased 20(OH)D3-
stimulated mRNA levels (Po0.0005) as compared with cells
transfected with scrambled siRNA.
Thus, these experiments clearly demonstrate the involve-
ment of VDR and VDRE in the phenotypic effects mediated
by 20(OH)D3. However, we cannot entirely exclude a
possibility that additional receptors, such as membrane-
associated receptors, with respective downstream signaling
pathways may also contribute, as suggested by others
(Johansen et al., 2003; Khanal and Nemere, 2007).
CONCLUSIONS
We have previously reported that hydroxy derivatives of
plant-derived ergosterol and ergocalciferol (vitamin D2),
produced by the action of P450scc (CYP11A1), have
biological actions on skin cells cultured in vitro (Slominski
et al., 2005a). In this paper, we report for the first time that the
major product of vitamin D3 metabolism catalyzed by
P450scc, 20(OH)D3 (Guryev et al., 2003; Slominski et al.,
2005b), acts as an inhibitor of cell proliferation and a
stimulator of keratinocyte differentiation, with a potency
comparable to that of 1,25(OH)2D3. Furthermore, its action
on the expression of CYP27B1, CYP27A1, and CYP24 genes
suggests a potential role in the regulation of 1,25(OH)2D3
production, which may depend on the cell type used.
20(OH)D3 acts through the VDR pathway, although activa-
tion of other pathways may also be involved. To conclude,
our report identifies for the first time 20(OH)D3 as a
biologically active secosteroid that is a potent stimulator of
epidermal keratinocyte differentiation. Thus, this secosteroid
produced by P450scc, in an alternate pathway of vitamin D3
metabolism (Slominski et al., 2004, 2005b), may play an
important role in cutaneous biology.
MATERIALS AND METHODS
The medical ethical committee of University of Tennessee Health
Science Center approved all described studies.
Synthesis and reversed-phase-HPLC purification of 20(OH)D3
Cytochrome P450scc purified from bovine adrenal glands was used
to hydroxylate vitamin D3 as described previously (Slominski et al.,
2005b) The main product, 20(OH)D3, was purified by preparative
thin-layer chromatography. Prior to use, the remaining impurities
were removed using an RF-HPLC system (Waters, Milford, MA)
equipped with C18 column (10 cm 5mm, particle size 4 mm;
Waters). An isocratic elution was performed with 82% methanol and
18% water at a flow rate of 1.5mlmin1 at 40 1C. UV spectra were
collected at 280 nm using 2487 Waters Dual l Absorbance Detector.
Fractions with vitamin D3 purity of at least at least 99% were
combined, dried under nitrogen, and stored at 70 1C. In order to
confirm the purity of the 20(OH)D3, the sample was dissolved in
absolute ethanol (15 ml), reapplied to the HPLC column and eluted
with a 50–100% of methanol gradient in water, at flow rate of
1.5mlmin1 at 40 1C. UV spectra were collected from 210 to
300 nm using Waters 991 PDA Detector. Mass spectra were
collected using a Bruker Esquire 3000 Plus Ion trap Mass Spectro-
meter MSD-Trap-XCT system (Agilent Technologies, Palo Alto, CA).
The system was operated with the atmospheric pressure chemical
ionization source in the positive ion mode. The scans (average of five
spectra) were collected between 100 and 500 m/z.
Proliferation and clonogenicity assays
HaCaT and human adult epidermal keratinocytes were cultured and
DNA synthesis experiment were performed as described previously
(Slominski et al., 2003). Cells were plated in six-well plates at a
density of 20 cells cm2 in DMEM (Cellgro, Herndon, VA) containing
5% charcoal-treated fetal bovine serum (FBS) (Hyclone, Logan, UT),
1% antibiotic solution (PSA; Sigma, St Louis, MI), and vehicle or
secosteroids. Cells were incubated at 37 1C for 10 days, with
media being changed every 3 days. Cells were fixed with 4%
paraformaldehyde in phosphate-buffered saline overnight, stained
with 0.5% crystal violet in phosphate-buffered saline for 15minutes,
rinsed, and air-dried. The number and size of the colonies were
measured using an ARTEK counter 880 (Dynex Technologies Inc.,
Chantilly, VA). Colony-forming units were calculated by dividing the
number of colonies (size40.5mm) by the number of cells plated
and then multiplying by 100.
DNA content and involucrin expression
Flow-cytometric DNA content and flow-cytometric and microscopic
analyses of involucrin expression were performed as described
previously (Slominski et al., 2003; Zbytek and Slominski, 2005).
Real-time reverse transcriptase–PCR for cytokeratin 14,
involucrin, CYP27A1, and CYP27B1
RNA was extracted using an Absolutely RNA RT–PCR Miniprep kit
(Stratagene, La Jolla, CA). Real-time PCR and reverse transcription
products were purchased from Applied Biosystems (Foster City, CA).
Reverse transcription was performed using Taqman reverse trans-
cription reagents. The following PCR products were used:
cytokeratin 14, Hs00265033_m1; involucrin, Hs00846307_s1;
CYP27A1, Hs00168003_m1; CYP27B1, Hs00168017_m1; and
18SrRNA, Hs99999901_s1. The reaction was performed with
Taqman Universal PCR Master Mix; data were collected with an
ABI Prism 7700 and analyzed with Sequence Detector 1.9.1.
Specific gene amounts were related to 18SrRNA by comparative Ct
method.
Real-time reverse transcriptase–PCR for CYP24
RNA was extracted as above. Reverse transcription was performed
with the Transcriptor first-strand cDNA synthesis kit (Roche,
Nutley, NJ). The primers (right: 50-GCA GCT CGA CTG GAG TGA
C-30; left: 50-CAT CAT GGC CAT CAA AAC AAT-30) and probe (cat.
no. 04689135001) were designed with the Universal Probe Library
(Roche). Real-time PCR was performed using TaqMan PCR Master
Mix at 50 1C for 2minutes, 95 1C for 10minutes, and then performing
50 cycles (95 1C for 15 seconds, 60 1C for 1minute). The data were
collected with a Roche Light Cycler 480. The amounts of CYP24
were normalized by comparative Ct method, using cyclophilin D as
a housekeeping gene.
CYP24-Luc transfection
The CYP24-Luc construct was a generous gift from Dr Tai Cheng
(Boston University Medical Campus, Core Lab Director). It was
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originally developed by Vaisanen et al. (2005). The details of the
pLuc construct and transfection have been described previously
(Pisarchik and Slominski, 2004; Zbytek et al., 2006).
VDRE electrophoretic mobility shift assay
HaCaT keratinocytes were treated for 24 hours. Nuclear extracts
were prepared as described previously (Zbytek et al., 2006). The
synthetic IRDye-labeled oligonucleotide (LI-COR Inc., Lincoln, NE)
used for the DNA mobility shift assay contained the wild-type VDRE
sequence, the sp1 promoter, and part of the involucrin sequence
(50-GCGGGAGGCAGATCTGGCAGATACTGA-30), as described
(Bikle et al., 2002). The DNA-binding reaction was set up using
2.5 mg of the nuclear extract, oligonucleotide, and buffer consisting
of 2.5mmol l1 dithiothreitol, 0.25% Tween-20, and 0.25mgml1
poly(dI):poly(dC). Samples were incubated at room temperature in
the dark for 30minutes and then run on 5% Tris/borate/EDTA gel at
80V for 1 hour. The gel was scanned using Odyssey Infrared Imaging
System (LI-COR).
VDRE-Luc and siRNA transfection
HaCaT keratinocytes were transfected with VDRE-Luc (gift from
Dr Thai Chen; Vaisanen et al., 2005) and/or with scrambled or VDR
siRNA (Dharmacon Inc., Lafayette, MO), on-Target plus smart pool
human VDR L-003448-00, on-Target plus siControl non-targeting
pool D-001810-10-05), using Lipofectamine Plus (Invitrogen,
Carlsbad, CA) in DMEM medium. PhRL-TK (expressing Renilla
luciferase) served as a normalization control (Promega, Madison,
WI). After transfection, cells were incubated for 24 hours in DMEM
with 5% FBS. Cells were then transferred to fresh media containing
the compounds to be tested or vehicle (ethanol) and incubated for
24 hours. Levels of VDR and b-actin 24 hours after transfection were
assessed by western blot (VDR(D-6) antibody, sc-13133, 1:400;
Santa Cruz Inc., Santa Cruz, CA) performed as described previously
(Hanissian et al., 2005).
Statistical analysis
Data are presented as mean±SEM and have been analyzed with
Student’s t-test (for two groups) or one-way analysis of variance, and
appropriate post hoc test (for more than two groups), using Excel
(Microsoft) and Prism 4.00 (GraphPad Software, San Diego, CA).
Statistically significant differences are denoted by asterisks as
follows: *Po0.05, **Po0.005, and ***Po0.0005.
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